---
document_datetime: 2025-07-17 14:59:11
document_pages: 16
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/zavicefta-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
document_name: zavicefta-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
version: success
processing_time: 7.5921285
conversion_datetime: 2025-12-22 13:45:46.439303
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Zavicefta

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                                                                          | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary                                                               |
|----------------------|--------------------------------------------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------------------------------------------------------------------|
| II/0035              | C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one | 19/09/2024                          | 21/10/2024                                  | SmPC and PL                      | Please refer to Scientific Discussion 'Zavicefta-H-C-004027- II-0035' |
| IB/0037/G            | This was an application for a group of variations.                                                                             | 15/10/2024                          | n/a                                         |                                  | Please refer to Scientific Discussion 'Zavicefta-H-C-004027- II-0035' |

1  Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.

2  A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.

3  SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

|         | C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Other variation B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Other variation B.I.a.2.z - Changes in the manufacturing process of the AS - Other variation B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process   |            |            |             |                                                                                                                    |
|---------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|--------------------------------------------------------------------------------------------------------------------|
| IA/0036 | A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | 30/04/2024 | n/a        |             |                                                                                                                    |
| II/0033 | Update of section 4.8 of the SmPC in order to add 'Kounis syndrome' to the list of adverse drug                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 25/01/2024 | 21/10/2024 | SmPC and PL | 'Kounis syndrome' is a serious adverse reaction to which healthcare professionals need to be alerted. Inclusion in |

<div style=\"page-break-after: always\"></div>

|                     | reactions (ADRs). A warning about this syndrome was also added to section 4.4, with a cross-reference to section 4.8. The Package Leaflet was updated accordingly. In addition, the MAH took the opportunity to introduce minor changes to the PI and to update the list of local representatives in the Package Leaflet. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data                                     |            |     | section 4.8 (under SOC 'Cardiac disorders') with a frequency unknown was implemented. Furthermore, information on this ADR was included in section 4.4 of the Zavicefta SmPC. The PL was updated accordingly. For more information, please refer to the Summary of Product Characteristics.   |
|---------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IB/0034/G           | This was an application for a group of variations. B.I.a.2.z - Changes in the manufacturing process of the AS - Other variation B.I.z - Quality change - Active substance - Other variation B.I.z - Quality change - Active substance - Other variation B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process | 03/01/2024 | n/a |                                                                                                                                                                                                                                                                                               |
| PSUSA/10513 /202302 | Periodic Safety Update EU Single assessment - ceftazidime / avibactam                                                                                                                                                                                                                                                                                                                                                                                                           | 28/09/2023 | n/a | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                             |
| IB/0032/G           | This was an application for a group of variations.                                                                                                                                                                                                                                                                                                                                                                                                                              | 04/07/2023 | n/a |                                                                                                                                                                                                                                                                                               |

<div style=\"page-break-after: always\"></div>

|                     | B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Other variation B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |            |            |             |                                   |
|---------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|-----------------------------------|
| PSUSA/10513 /202202 | Periodic Safety Update EU Single assessment - ceftazidime / avibactam                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | 29/09/2022 | n/a        |             | PRAC Recommendation - maintenance |
| IB/0029             | B.II.f.1.a.3 - Stability of FP - Reduction of the shelf life of the finished product - After dilution or reconstitution                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 22/04/2022 | 26/04/2023 | SmPC and PL |                                   |
| II/0027/G           | This was an application for a group of variations. B.II.b.4.z - Change in the batch size (including batch size ranges) of the finished product - Other variation B.II.b.3.b - Change in the manufacturing process of the finished or intermediate product - Substantial changes to a manufacturing process that may have a significant impact on the quality, safety and efficacy of the medicinal product B.I.a.1.b - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Introduction of a manufacturer of the AS supported by an ASMF A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient | 24/02/2022 | n/a        |             |                                   |

<div style=\"page-break-after: always\"></div>

|                     | B.II.d.2.z - Change in test procedure for the finished product - Other variation B.II.c.2.d - Change in test procedure for an excipient - Other changes to a test procedure (including replacement or addition) B.II.c.2.d - Change in test procedure for an excipient - Other changes to a test procedure (including replacement or addition) B.II.d.2.z - Change in test procedure for the finished product - Other variation B.II.b.1.f - Replacement or addition of a manufacturing site for part or all of the manufacturing process of the FP - Site where any manufacturing operation(s) take place, except batch release, batch control, and secondary packaging, for sterile medicinal products (including those that are aseptically manufactured) excluding biological/ immunological medicinal products B.II.b.1.f - Replacement or addition of a manufacturing site for part or all of the manufacturing process of the FP - Site where any manufacturing operation(s) take place, except batch release, batch control, and secondary packaging, for sterile medicinal products (including those that are aseptically manufactured) excluding biological/   |            |            |    |                                   |
|---------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----|-----------------------------------|
| N/0028              | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | 01/10/2021 | 26/04/2023 | PL |                                   |
| PSUSA/10513 /202102 | Periodic Safety Update EU Single assessment - ceftazidime / avibactam                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 30/09/2021 | n/a        |    | PRAC Recommendation - maintenance |

<div style=\"page-break-after: always\"></div>

| II/0025/G   | This was an application for a group of variations.   | 15/04/2021   | n/a   |
|-------------|------------------------------------------------------|--------------|-------|

<div style=\"page-break-after: always\"></div>

<!-- image -->

| B.II.e.2.b - Change in the specification parameters and/or limits of the immediate packaging of the finished product - Addition of a new specification parameter to the specification with its corresponding test method B.II.e.2.b - Change in the specification parameters and/or limits of the immediate packaging of the finished product - Addition of a new specification parameter to the specification with its corresponding test method B.II.e.2.b - Change in the specification parameters and/or limits of the immediate packaging of the finished product - Addition of a new specification parameter to the specification with its corresponding test method B.II.e.2.b - Change in the specification parameters and/or limits of the immediate packaging of the finished product - Addition of a new specification parameter to the specification with its corresponding test method B.III.2.z - Change to comply with Ph. Eur. or with a national pharmacopoeia of a Member State - Other variation B.III.2.a.2 - Change of specification(s) of a former non EU Pharmacopoeial substance to fully comply with the Ph. Eur. or with a national pharmacopoeia of a Member State - Excipient/AS starting material B.II.d.2.z - Change in test procedure for the finished product - Other variation B.II.d.2.z - Change in test procedure for the finished product - Other variation   |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

<div style=\"page-break-after: always\"></div>

| product - Other variation B.II.d.2.z - Change in test product - Other variation B.II.d.2.z - Change in test product - Other variation B.II.d.2.z - Change in test product - Other variation B.II.d.2.z - Change in test product - Other variation B.II.d.2.z - Change in test product - Other variation B.II.d.1.e - Change in the and/or limits of the finished outside the approved specifications B.II.b.4.z - Change in the size ranges) of the finished B.II.b.3.b - Change in the the finished or intermediate changes to a manufacturing significant impact on the of the medicinal product B.II.b.2.a - Change to importer, arrangements and quality Replacement/addition of control/testing takes place B.II.b.1.f - Replacement manufacturing site for part manufacturing process manufacturing operation(s) release, batch control, and sterile medicinal products   |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

<div style=\"page-break-after: always\"></div>

|           | immunological medicinal products B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate B.I.b.1.d - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Deletion of a non- significant specification parameter (e.g. deletion of an obsolete parameter) B.I.a.1.b - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Introduction of a manufacturer of the AS supported by an ASMF A.7 - Administrative change - Deletion of manufacturing sites B.III.2.z - Change to comply with Ph. Eur. or with a national pharmacopoeia of a Member State - Other   |            |            |                       |
|-----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------------------|
| R/0024    | Renewal of the marketing authorisation.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 10/12/2020 | 11/02/2021 | SmPC, Annex II and PL |
| II/0023/G | This was an application for a group of variations. A.7 - Administrative change - Deletion of manufacturing sites B.I.a.1.f - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Changes to quality control testing arrangements for                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | 28/01/2021 | n/a        |                       |

<div style=\"page-break-after: always\"></div>

| batch control/testing takes B.I.a.1.f - Change in the starting material/reagent/intermediate Changes to quality control the AS -replacement or batch control/testing takes B.I.a.1.g - Change in the starting material/reagent/intermediate Introduction of a new manufacturer not supported by an ASMF update to the relevant B.I.a.1.g - Change in the starting material/reagent/intermediate Introduction of a new manufacturer not supported by an ASMF update to the relevant B.I.b.2.a - Change in test starting material/reagent/intermediate changes to an approved B.I.b.2.e - Change in test starting material/reagent/intermediate changes to a test procedure or addition) for the AS material/intermediate B.I.b.2.e - Change in test starting material/reagent/intermediate changes to a test procedure or addition) for the AS material/intermediate B.I.c.2.b - Change in the and/or limits of the immediate   |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

<div style=\"page-break-after: always\"></div>

specification with its corresponding test method B.I.c.2.b - Change in the specification parameters and/or limits of the immediate packaging of the AS Addition of a new specification parameter to the specification with its corresponding test method B.I.c.2.b - Change in the specification parameters and/or limits of the immediate packaging of the AS Addition of a new specification parameter to the specification with its corresponding test method B.I.c.2.b - Change in the specification parameters and/or limits of the immediate packaging of the AS Addition of a new specification parameter to the specification with its corresponding test method B.I.c.2.b - Change in the specification parameters and/or limits of the immediate packaging of the AS Addition of a new specification parameter to the specification with its corresponding test method B.I.c.2.b - Change in the specification parameters and/or limits of the immediate packaging of the AS Addition of a new specification parameter to the specification with its corresponding test method B.I.c.2.b - Change in the specification parameters and/or limits of the immediate packaging of the AS Addition of a new specification parameter to the specification with its corresponding test method B.I.c.2.b - Change in the specification parameters and/or limits of the immediate packaging of the AS Addition of a new specification parameter to the specification with its corresponding test method B.I.c.2.b - Change in the specification parameters and/or limits of the immediate packaging of the AS Addition of a new specification parameter to the

<div style=\"page-break-after: always\"></div>

<!-- image -->

|         | specification with its corresponding test method                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |            |            |             |                                                                      |
|---------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|----------------------------------------------------------------------|
| II/0015 | Extension of indication to include paediatric patients aged 3 months to less than 18 years for Zavicefta (for the treatment of cIAI and cUTI, HAP/VAP and aerobic Gram-negative infections in patients with limited treatment options), based on data from paediatric studies D4280C00014, C3591004 and C3591005 and the population PK modelling/simulation analyses (CAZ-MS-PED-01 and CAZ-MS-PED-02). As a consequence, sections 4.1, 4.2, 4.4, 4.8, 5.1, 5.2, 6.3 and 6.6 of the SmPC are updated in order to reflect this additional population, the paediatric posology, paediatric safety information, the description of the clinical trials and handling instructions for paediatric dosing. The Package Leaflet is updated in accordance. A warning was included in section 4.4 of the SmPC, with a cross-reference to section 4.9, to highlight a potential risk of overdosing for the youngest children from 3 months to less than 12 months of age, related to the difficulties to calculate the volume of administration of the dose. In addition, a table with dosing volumes calculated based on different weights was added to section 6.6. The Marketing authorisation holder (MAH) took the opportunity to correct the sodium content to SmPC sections 2 and 4.4 and PL section 2 and the volumes of distribution of ceftazidime and avibactam in SmPC section 5.2. The RMP version 3.2 has been approved with this | 17/09/2020 | 22/10/2020 | SmPC and PL | Please refer to Scientific Discussion 'Zavicefta -H-C-4027- II-0015' |

<div style=\"page-break-after: always\"></div>

|                     | C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |            |            |                       |                                                                        |
|---------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------------------|------------------------------------------------------------------------|
| PSUSA/10513 /202002 | Periodic Safety Update EU Single assessment - ceftazidime / avibactam                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | 01/10/2020 | n/a        |                       | PRAC Recommendation - maintenance                                      |
| II/0019             | Extension of Indication to include bacteraemia (in association with, or suspected to be associated with, the currently approved indications for complicated intra-abdominal infection (cIAI), complicated urinary tract infection (cUTI) and hospital-acquired pneumonia, including ventilator-associated pneumonia (HAP/VAP)) for Zavicefta; as a consequence, sections 4.1 and 4.2 of the SmPC are updated in order to add this indication and the posology. Furthermore, the PI is brought in line with the latest QRD template version 10.1. The Package Leaflet is updated in accordance. C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or | 25/06/2020 | 06/08/2020 | SmPC, Annex II and PL | Please refer to Scientific Discussion 'Zavicefta-H-C- 0004027-II-0019' |
| IAIN/0021           | A.5.a - Administrative change - Change in the name and/or address of a manufacturer/importer responsible for batch release                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 20/02/2020 | 06/08/2020 | Annex II and PL       |                                                                        |
| N/0020              | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | 02/12/2019 | 06/08/2020 | PL                    |                                                                        |

<div style=\"page-break-after: always\"></div>

| PSUSA/10513 /201902   | Periodic Safety Update EU Single assessment - ceftazidime / avibactam                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | 05/09/2019   | n/a        |                        | PRAC Recommendation - maintenance   |
|-----------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|------------------------|-------------------------------------|
| IB/0018               | B.II.b.3.z - Change in the manufacturing process of the finished or intermediate product - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                  | 17/06/2019   | n/a        |                        |                                     |
| N/0016                | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 09/04/2019   | 06/08/2020 | PL                     |                                     |
| PSUSA/10513 /201808   | Periodic Safety Update EU Single assessment - ceftazidime / avibactam                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | 14/03/2019   | n/a        |                        | PRAC Recommendation - maintenance   |
| N/0013                | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 24/10/2018   | 25/02/2019 | PL                     |                                     |
| PSUSA/10513 /201802   | Periodic Safety Update EU Single assessment - ceftazidime / avibactam                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | 06/09/2018   | n/a        |                        | PRAC Recommendation - maintenance   |
| II/0009               | The SmPC section 4.2 has been updated as follows: Paediatric population Safety and efficacy in children and adolescents below 18 years of age have not yet been established. Currently available data are described in section 4.8 but no recommendation on a posology can be made. The SmPC section 4.3 has been updated as follows: Controlled sodium diet Each vial contains a total of 6.44 mmol of sodium (approximately 148 mg), equivalent to 7.4% of the WHO recommended maximum daily intake for sodium. The maximum daily dose of this product is | 14/06/2018   | 25/02/2019 | SmPC, Labelling and PL |                                     |

<div style=\"page-break-after: always\"></div>

|                     | maximum daily intake for sodium. The SmPC section 4.8 has been updated as follows: Paediatric population The safety assessment in children is based on the safety data from 1 trial in which 61 paediatric patients aged from 3 months to less than18 years with cIAI received Zavicefta. Overall, the safety profile in these 61 children was similar to that observed in the adult population with cIAI. The PL has been updated accordingly. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data   |            |            |                        |                                   |
|---------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|-----------------------------------|
| II/0008             | C.I.11.b - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Implementation of change(s) which require to be further substantiated by new additional data to be submitted by the MAH where significant assessment is required                                                                                                                                                                                                                                                                      | 12/04/2018 | n/a        |                        |                                   |
| PSUSA/10513 /201708 | Periodic Safety Update EU Single assessment - ceftazidime / avibactam                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | 08/03/2018 | n/a        |                        | PRAC Recommendation - maintenance |
| IAIN/0010           | A.1 - Administrative change - Change in the name and/or address of the MAH                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | 12/02/2018 | 25/02/2019 | SmPC, Labelling and PL |                                   |
| PSUSA/10513 /201702 | Periodic Safety Update EU Single assessment - ceftazidime / avibactam                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | 28/09/2017 | n/a        |                        | PRAC Recommendation - maintenance |

<div style=\"page-break-after: always\"></div>

| T/0006              | Transfer of Marketing Authorisation                                                                               | 23/06/2017   | 19/07/2017   | SmPC, Labelling and PL           |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
|---------------------|-------------------------------------------------------------------------------------------------------------------|--------------|--------------|----------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| PSUSA/10513 /201608 | Periodic Safety Update EU Single assessment - ceftazidime / avibactam                                             | 09/03/2017   | n/a          |                                  | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| II/0002             | C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data | 23/02/2017   | 19/07/2017   | SmPC, Annex II, Labelling and PL | The MAH has updated: - section 4.4 of the SmPC to reflect that clinical efficacy and safety studies of Zavicefta have been conducted in patients with Hospital Acquired Pneumonia (HAP) including Ventilator-Associated Pneumonia (VAP): 'In a single study in patients with nosocomial pneumonia 280/808 (34.7%) had VAP and 40/808 (5.0%) were bacteraemic at baseline' ; - section 4.8 to change the frequency of thrombocytopenia and pruritus from uncommon to common - section 5.1 to add a new section for HAP/VAP pathogens: 'Hospital-acquired pneumonia including ventilator- associated pneumonia Gram-negative micro-organisms  Enterobacter cloacae  Escherichia coli  Klebsiella pneumoniae  Proteus mirabilis  Serratia marcescens  Pseudomonas aeruginosa'. |
| N/0003              | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                  | 01/02/2017   | 19/07/2017   | PL                               |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |